Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2/3 study of BPM31510 in primary CoQ10 deficiency

Next Previous
Trial Profile

A Phase 2/3 study of BPM31510 in primary CoQ10 deficiency

Status: Planning
Phase of Trial: Phase II/III

Latest Information Update: 26 Jun 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ubidecarenone (Primary)
  • Indications Cancer; Pancreatic cancer
  • Focus Registrational; Therapeutic Use

Most Recent Events

  • 17 Jun 2026 According to a BPGbio media release, company is planning a Phase 3 pivotal trial of BPM31510 for primary CoQ10 deficiency following a Type C meeting with the U.S. Food and Drug Administration (FDA) earlier this spring,
  • 08 Oct 2024 According to a BPGbio, Inc. media release, company is planning phases for late-stage Phase 2/3 trial for PCQD.
  • 30 Sep 2024 According to a BPGbio media release, the company is planning a potential pivotal trial of BPM31510IV targeting multiple CoQ10 deficiency mutations at multiple US and EU sites.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top